WWB

25.76014.25%

2 Reasons Windward Bio Group (WWB) Looks Pricey Following Its Shelf Filing

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Windward Bio Group (NasdaqGS:WWB) has moved quickly after its US listing by filing a US$144.2 million shelf registration for 8,483,040 common shares tied to an employee stock ownership plan.

That move comes on the heels of a rapid debut for Windward Bio Group, with the stock now at US$28.50 after its IPO was priced at US$17 per share and a 1 day share price return of 67.65% that also matches its year to date share price return.

Scan other fast-moving biotech listings alongside Windward Bio Group with our hand picked 19 high quality undiscovered gems, which have strong fundamentals and are still flying under most investors radars.

Windward Bio Group now trades well above its IPO price after a sharp first day jump. The key issue is whether that move already reflects the story or still leaves room on the table.

Preferred Price-To-Book of 6.2x: Is it justified?

On a simple yardstick, Windward Bio Group looks expensive. At a last close of $28.50, the stock carries a P/B ratio of 6.2x, while peers on average change hands at 2.7x.

P/B compares the market value of the equity to the accounting value of net assets. It tends to matter most for early stage biotechs like Windward Bio Group that have little or no revenue, because investors often focus on cash, intellectual property and trial stage assets rather than current earnings.

With virtually no revenue reported and the business still loss making, a P/B of 6.2x suggests buyers are paying a much higher multiple of book value than is seen across similar US companies. The gap is even wider against the broader US biotechs group, which sits at 1.8x P/B, so the market appears willing to assign a richer valuation to this pipeline and balance sheet than to the sector average.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 6.2x (OVERVALUED)

Still, the story around Windward Bio Group can change quickly if trial data disappoints or if funding needs escalate faster than the balance sheet can support.

Find out about the key risks to this Windward Bio Group narrative.

Next Steps

Feeling unsure whether Windward Bio Group now looks stretched or just fully priced is normal. Move quickly to review the data and stress test your own thesis, starting with its 3 important warning signs.

Looking for more Windward Bio Group investment ideas?

If Windward Bio Group feels fully priced for now, do not sit on your hands. Use this moment to line up your next set of potential opportunities with targeted screeners that filter for quality, resilience and income.

  • Target resilient balance sheets by scanning a list of solid balance sheet and fundamentals (24 results) that filters for companies with stronger financial footing and cleaner fundamentals.
  • Hunt for potential value by reviewing a 34 high quality undervalued stocks that highlights stocks with solid cash flows and supportive balance sheets.
  • Build a cash flow cushion by shortlisting income ideas through a 6 dividend fortresses focused on higher yielding dividend payers.

Source: Simplywall The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.